It is now clear that the "one or two mistakes" were in fact overwhelming problems, but phasing out the LCP still leaves the problems it was created to resolve

Billionaire hedge fund boss Steve Cohen is likely to escape criminal charges over one of the biggest cases of alleged insider dealing as US prosecutors fail to come up with enough evidence against him before a deadline at the end of this month.

A local official said an agreement of pay was reached with "mutual satisfaction"

Tests have established a direct link between the Duke of Cambridge and a woman believed to have been at least half Indian

Shares in Oxford BioMedica plunged 28 per cent yesterday as the biopharmaceutical company put some of its trials on hold after discovering "potential impurities" in one of its raw materials.

Eurostar has appointed its first female chairman, with Clare Hollingsworth set to take over from the incumbent Richard Brown in June. Ms Hollingsworth was chief executive of the private hospital group Spire Healthcare, and managing director of Caledonian Airways.

Gene therapy is one of those medical "breakthroughs" that has unfortunately failed to live up to expectations. Several clinical trials, usually involving inherited diseases caused by defects in single genes, have ended in failure and, in at least one case, the death of patients.

AstraZeneca could be heading for a pay storm at its upcoming AGM after the biggest grouping of public-sector pension funds were advised to vote down a remuneration plan that sees the drugmaker’s new chief executive pocket £6.5m after just three months’ work.

Mitochondrial replacement could help families at risk of a certain class of genetic disorders

Reckitt Benckiser's former finance director Colin Day has wasted little time in his new role as the chief executive of plastic products supplier Filtrona.

A many-splendored (and bloodthirsty) thing

How dare we subject what little we have left of Britain's utopian vision to the same complaint culture that we would a day-trip that didn’t live up to our expectations?

GlaxoSmithKline could sell Lucozade and Ribena after Britain’s biggest pharmaceuticals firm today set out plans for a “strategic review” of the drinks brands.

Pharmaceutical giant shocks medical world by opting to reveal findings of all tests on patients